# Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma

> **NCT02136134** · PHASE3 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 498 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Daratumumab
- **DRUG:** VELCADE (Bortezomib)
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT02136134
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-08-15
- **Primary completion:** 2016-01-11
- **Final completion:** 2024-01-10
- **Target enrollment:** 498 (ACTUAL)
- **Last updated:** 2025-08-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02136134

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02136134, "Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02136134. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*